Cravatex Limited (509472) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Cravatex Limited ₹338, price ₹346, upside -2.2%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cravatex Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹224.42 – ₹629.67 · fair‑value band ₹328.76 – ₹355.53 · the ₹346.05 price screens above the ₹338.32 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Cravatex in your weekly email
Every Wednesday you see whether Cravatex is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cravatex Limited, through its subsidiaries, deals in consumer brands, sports goods, and fitness equipment business in India, the United Kingdom, Ireland, Europe, the Middle East, the United States, Nepal, Sri lanka etc. The company operates through Sports and Wellness segments.
Show more
Cravatex Limited, through its subsidiaries, deals in consumer brands, sports goods, and fitness equipment business in India, the United Kingdom, Ireland, Europe, the Middle East, the United States, Nepal, Sri lanka etc. The company operates through Sports and Wellness segments. It is involved in trading footwear, apparel, gym equipment, and related accessories; and the retail sale of fitness equipment. In addition, the company engages in designing, sourcing, and marketing branded apparel and footwear as a licensee for the Fila brand. Cravatex Limited was incorporated in 1951 and is headquartered in Mumbai, India. Cravatex Limited is a subsidiary of R.B. Fitness and Trading Private Limited.
Stock analysis
Cravatex Limited (509472) currently trades at ₹346.05, while our model-based Fair Value estimate is ₹338.32, so the stock looks roughly fairly valued today (gap 2.3%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹447.12 per share, and 10 of the 17 models we run sit above the ₹346.05 price.
Bear case: the Dividend Discount group reads lowest at ₹119.64, and 7 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹328.76 (bear) to ₹355.53 (bull), the price of ₹346.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Consumer Discretionary sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Cravatex Limited reported revenue of ₹1.5B in FY2026 versus ₹5.9B in FY2022, a compound −29.0%/yr. Reported net income was ₹68.0M in FY2026.
Key figures
Market cap ₹894M (≈ $9.3M) · P/S ratio 0.10 · EPS (TTM) ₹−33.08 · Dividend yield 1.4% · Net margin 4.5% · Return on assets (EBIT) 4.8% · Operating margin −0.1% · Revenue growth (YoY) −67.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Discretionary peers we cover trades at 12% fair-value upside, at −2%, 509472 screens richer than that median.
Fair Value models
Bear ₹328.76Fair Value ₹338.32Bull ₹355.53
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.26/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−13.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−33.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.3%
Start year 2021 (pandemic). Over 10 years: −5.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−38.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−40.3%
Dividend (yield on the price)1.4%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → −5%
⚠ Revenue per share shrinking 9.7%/yr over ~7Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Leisure Products” was too small, so the broader sector is used.)Consumer Discretionary · 3564 stocks
Beats the sector median on 2/8 measures
Overall it trails its sector peers.
Valuation
Quality Score59 · Above median
Fair Value upside+3.0% · Below median
Profitability
Return on assets0.0% · Bottom 25%
Net margin (TTM)−1.7% · Bottom 25%
Operating margin (TTM)−0.1% · Bottom 25%
Growth and dividend
Revenue growth−67.2% · Bottom 25%
Dividend yield (TTM)1.4% · Below median
Valuation Multiplesvs Consumer Discretionary median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cravatex Limited Fair Value". https://www.fairvalue-calculator.com/stock/509472
Frequently asked questions
Is Cravatex Limited (509472) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹338.32 versus a price of ₹346.05, about −2% upside (fairly valued).
What is the fair value of 509472?
Our model-based fair value for Cravatex Limited is ₹338.32 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹346.05.
What is the quality score of 509472?
Cravatex Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cravatex Limited (509472)?
Our model-based price target is the fair value of ₹338.32 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ₹328.76, optimistic scenario ₹355.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Cravatex Limited stock forecast for 2026?
Our models put fair value at ₹338.32, about −2% upside versus a price of ₹346.05 (fairly valued). Cautious scenario ₹328.76, optimistic scenario ₹355.53. The calculation is refreshed regularly with new filings.
Does Cravatex Limited pay a dividend?
Cravatex Limited currently shows a dividend yield of about 1.44% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Cravatex Limited (509472)?
For today's price to be fair in a discounted-cash-flow model, Cravatex Limited would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -22.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 509472 use?
Our models discount Cravatex Limited at 10.9 %: a base by market capitalisation (nano), damped by beta 0.50, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cravatex Limited that is less than minus 40 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Cravatex Limited (509472) delivered so far?
Over the past 5 years revenue at Cravatex Limited grew -22.3 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cravatex Limited (509472) growing?
The median revenue growth in the sector is +7.6 % a year. That is the yardstick for the growth priced into Cravatex Limited (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cravatex Limited (509472)?
The free-cash-flow yield on the price is 0.98 %: that much free cash flow Cravatex Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cravatex Limited (509472)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cravatex Limited it is ₹338.32 per share (as of Sep 24, 2026), against a price of ₹346.05. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Cravatex Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 509472 trades above its calculated fair value: price ₹346.05, fair value ₹338.32, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 509472?
No. The price is what the market pays today (₹346.05); the fair value is what the company's own numbers justify (₹338.32). For Cravatex Limited the two are ₹7.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cravatex Limited worth?
The market values Cravatex Limited at about ₹894M (market capitalisation, as of Sep 24, 2026). Per share that is ₹346.05; our models calculate a fair value of ₹338.32 per share.
What do the bullish and bearish scenarios say about 509472?
Our models span a range for Cravatex Limited: cautious scenario ₹328.76, base ₹338.32, optimistic ₹355.53 per share (as of Sep 24, 2026, price ₹346.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 509472 from its 52-week high?
Cravatex Limited trades at ₹346.05, about 18% below its 52-week high of ₹420.80 and 13% above the low of ₹305.20 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹338.32 is for.
Which stocks are comparable to Cravatex Limited?
From the same area (Consumer Discretionary) we also value GOLFZON NEWDIN HOLDINGS Co, Aurora World Corporation, SONOKONG Co, VC Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cravatex Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹346.05, calculated fair value ₹338.32 (−2%), Quality Score 59/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 509472 calculated?
We run Cravatex Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹338.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cravatex Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cravatex Limited (509472)?
The closing price on Oct 1, 2026 was ₹346.05. Our model-based fair value is ₹338.32, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cravatex Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (₹328.76 to ₹355.53), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Cravatex Limited
How large is the market capitalisation of Cravatex Limited (509472)?
The market capitalisation of Cravatex Limited is ₹894M (≈ $9.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cravatex Limited (509472)?
The price-to-sales ratio of Cravatex Limited is 0.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cravatex Limited (509472)?
Earnings per share at Cravatex Limited are ₹−33.08. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cravatex Limited (509472)?
The dividend yield of Cravatex Limited is 1.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cravatex Limited (509472)?
The net margin of Cravatex Limited is 4.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Cravatex Limited (509472)?
On an EBIT basis the return on assets of Cravatex Limited is 4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cravatex Limited (509472)?
The operating margin of Cravatex Limited is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cravatex Limited (509472)?
Revenue at Cravatex Limited is growing −67.2% versus a year earlier (3y avg −33.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Cravatex Limited (509472) carry?
The net debt of Cravatex Limited is ₹1.3B (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cravatex Limited in the live analysis
One click puts Cravatex Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
